FDA Approves Rituximab Combination Across Multiple Pediatric Cancer Indications
December 3rd 2021FDA approves rituximab (Rituxan) plus chemotherapy for pediatric patients with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia.
Read More
Considerations for Environmentally Conscious Pharmacy Students
Environmental conditions and air pollution affect health by causing injuries and fatalities, exacerbating respiratory and cardiovascular diseases, and spreading infectious diseases.
Read More